View : 373 Download: 193

Full metadata record

DC Field Value Language
dc.contributor.author사홍기-
dc.date.accessioned2016-08-28T10:08:50Z-
dc.date.available2016-08-28T10:08:50Z-
dc.date.issued2013-
dc.identifier.issn1176-9114-
dc.identifier.otherOAK-10009-
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/223656-
dc.description.abstractThe functionality of bare polylactide-co-glycolide (PLGA) nanoparticles is limited to drug depot or drug solubilization in their hard cores. They have inherent weaknesses as a drug-delivery system. For instance, when administered intravenously, the nanoparticles undergo rapid clearance from systemic circulation before reaching the site of action. Furthermore, plain PLGA nanoparticles cannot distinguish between different cell types. Recent research shows that surface functionalization of nanoparticles and development of new nanoparticulate dosage forms help overcome these delivery challenges and improve in vivo performance. Immense research efforts have propelled the development of diverse functional PLGA-based nanoparticulate delivery systems. Representative examples include PEGylated micelles/nanoparticles (PEG, polyethylene glycol), polyplexes, polymersomes, core-shell-type lipid-PLGA hybrids, cell-PLGA hybrids, receptor-specific ligand-PLGA conjugates, and theranostics. Each PLGA-based nanoparticulate dosage form has specific features that distinguish it from other nanoparticulate systems. This review focuses on fundamental concepts and practices that are used in the development of various functional nanoparticulate dosage forms. We describe how the attributes of these functional nanoparticulate forms might contribute to achievement of desired therapeutic effects that are not attainable using conventional therapies. Functional PLGA-based nanoparticulate systems are expected to deliver chemotherapeutic, diagnostic, and imaging agents in a highly selective and effective manner. © 2013 Sah et al, publisher and licensee Dove Medical Press Ltd.-
dc.languageEnglish-
dc.titleConcepts and practices used to develop functional PLGA-based nanoparticulate systems-
dc.typeReview-
dc.relation.volume8-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.startpage747-
dc.relation.lastpage765-
dc.relation.journaltitleInternational Journal of Nanomedicine-
dc.identifier.doi10.2147/IJN.S40579-
dc.identifier.wosidWOS:000317922700068-
dc.identifier.scopusid2-s2.0-84874357219-
dc.author.googleSah H.-
dc.author.googleThoma L.A.-
dc.author.googleDesu H.R.-
dc.author.googleSah E.-
dc.author.googleWood G.C.-
dc.contributor.scopusid사홍기(56127728100)-
dc.date.modifydate20190901081003-
Appears in Collections:
약학대학 > 약학과 > Journal papers
Files in This Item:
001.pdf(1.47 MB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE